Physician profile
Bradley Shepherd
NPI 1649327594
$9,722.99
in general payments reported to CMS, 2019-2025
40 companies · $2,100 in 2025
The $2,100 reported for 2025 was more than what 80% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $676 · 2020: $1,299 · 2021: $1,031 · 2022: $1,453 · 2023: $1,523 · 2024: $1,640 · 2025: $2,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,262.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,398.82 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,088.65 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Boston Scientific Corporation | $789.97 | 2020-2025 | General - Therapies, Endoarmor |
| Takeda Pharmaceuticals U.S.A., INC. | $783.87 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $747.96 | 2019-2025 | Stelara, Tremfya |
| Genzyme Corporation | $641.33 | 2022-2025 | |
| Pfizer INC. | $597.01 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $316.65 | 2020-2024 | Ocaliva |
| Qol Medical, LLC | $252.51 | 2019-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $235.14 | 2024-2025 | Omvoh, Zepbound |
| Regeneron Healthcare Solutions, INC. | $223.23 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $168.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Celgene Corporation | $165.39 | 2021-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $156.75 | 2024-2025 | Iqirvo |
| Gilead Sciences, INC. | $122.81 | 2019-2025 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $105.91 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $91.85 | 2019-2023 | Dificid |
| Ucb, INC. | $89.92 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $79.75 | 2019-2022 | |
| Sandoz INC. | $76.58 | 2023-2024 | Hyrimoz |
| Evoke Pharma, INC. | $62.61 | 2020-2023 | Gimoti |
| Braintree Laboratories, INC. | $59.89 | 2020-2025 | Sutab, Suflave |
| Nestle Healthcare Nutrition INC. | $52.75 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $50.95 | 2020-2023 | Rebyota |
| Organon LLC | $44.39 | 2024-2025 | Renflexis, Hadlima |
| Mallinckrodt Hospital Products INC. | $40.11 | 2024-2025 | Terlivaz |
| Phathom Pharmaceuticals, INC. | $37.30 | 2024-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $31.56 | 2023 | |
| Romark Laboratories, Lc | $25.74 | 2019-2020 | |
| Amgen INC. | $23.40 | 2023 | Avsola, Amjevita |
| Celltrion USA INC. | $23.38 | 2025 | Vegzelma |
| Vivus LLC | $21.55 | 2021 | |
| Daiichi Sankyo INC. | $18.52 | 2020 | |
| Olympus America INC. | $16.55 | 2020 | |
| Aimmune Therapeutics, INC. | $15.82 | 2024 | |
| Ethicon US, LLC | $15.45 | 2022 | |
| Medtronic, INC. | $13.78 | 2025 | Interstim |
| Redhill Biopharma INC. | $13.31 | 2020 | |
| Coloplast Corp | $12.77 | 2019 | |
| Mauna Kea Technologies, INC. | $10.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Shepherd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.